Document is current
Any future updates will be listed below
-
Authors
Andrejeva, Gabriela
Capoccia, Benjamin
Delston, Rachel
Donio, Michael
Hiebsch, Ronald
Puro, Robyn
Wilson, Casey
Kashyap, Arun
Pereira, Daniel
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03834948 at ClinicalTrials.govnct04445701 at ClinicalTrials.govDocuments that mention this clinical trial
260 CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics
https://doi.org/10.1136/jitc-2021-sitc2021.260
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
https://doi.org/10.1136/jitc-2020-sitc2020.0215
Documents that mention this clinical trial
260 CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics
https://doi.org/10.1136/jitc-2021-sitc2021.260
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
https://doi.org/10.1136/jitc-2020-sitc2020.0215
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
